Who is a candidate for PRP? Indications and contraindications
Patient selection for PRP rests on evidence strength by condition, consensus contraindications and honest consent. This guide covers the principles.

Key takeaways.
- Evidence for PRP varies widely by condition, so selection starts with the diagnosis.
- The course rates evidence strongest for lateral epicondylitis and mild to moderate knee osteoarthritis.
- Evidence does not support PRP for Achilles tendinopathy or acute muscle injuries.
- A 2025 international consensus (GRIIP) issued 23 recommendations on contraindications.
- Most contraindications are relative and call for an individual risk and benefit assessment.
- PRP is not FDA-approved for any indication, and its applications are considered off-label.
Selection starts with the evidence
The research behind PRP differs greatly from one condition to another. The course places lateral epicondylitis (tennis elbow) and mild to moderate knee osteoarthritis in the group with abundant high-quality evidence. Patellar tendinopathy and plantar fasciitis sit in a moderate group.
Some uses have negative or insufficient evidence. Reviews have not shown a meaningful benefit in Achilles tendinopathy. Randomized trials in acute muscle injury have not shown faster return to play.
Contraindications: the 2025 consensus
The International Research Group on Platelet Injections (GRIIP) published a formal consensus in 2025. It used a Delphi process, meaning repeated rounds of expert voting, and produced 23 recommendations. It focused on infectious, oncological and hematological conditions.
Absolute contraindications in the course material are critical thrombocytopenia (a very low platelet count), platelet dysfunction syndromes, hemodynamic instability, and sepsis or infection at the injection site. Most other contraindications are relative. They require a case-by-case judgment of risk and benefit.
Evaluation and follow-up
Pre-treatment evaluation confirms the diagnosis, screens for contraindications and records a baseline. It typically includes a history, a focused examination and a complete blood count.
Follow-up should use validated outcome measures. These are standard questionnaires that show whether a change is clinically meaningful, not just measurable.
Consent and regulatory status
Therapeutic misconception is a central risk. It means a patient's hope leads them to overestimate the likely benefit or to miss that a treatment is investigational. Clinicians should explain where the patient's condition sits on the evidence spectrum.
PRP made from a patient's own blood with minimal manipulation does not require FDA premarket approval. That is not the same as being FDA-approved. The FDA has not formally evaluated its safety and efficacy for specific indications. PRP applications are considered off-label.
Educational content for healthcare professionals. Not a treatment recommendation. PRP applications are considered off-label.
This guide covers the what and the why.
The how is taught live. The webinar and live training go deeper on:
- Appropriateness criteria for knee osteoarthritis
- Relative contraindications and how to handle them
- Pre-treatment work-up and prognostic factors
- Consent conversations and expectation setting
- Choosing and scheduling outcome measures
Common questions.
What are the absolute contraindications to PRP?
Is PRP FDA-approved?
Which conditions are poor candidates for PRP?
Sources
- Kon E, et al. Platelet-rich plasma injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios. Knee Surg Sports Traumatol Arthrosc. 2024;32(4):908-928.
- Baria M, et al. Current clinical recommendations for use of platelet-rich plasma. Curr Rev Musculoskelet Med. 2018;11(4):624-634.
- Jayaram P, Danilkowicz RM, Yuan X. Ethical and regulatory considerations related to regenerative medicine. Cell Transplant. 2025;34:9636897251361511.
Keep reading.
PRP · 3 min read
Can PRP be combined with other treatments?
PRP is studied alongside hyaluronic acid, surgery, energy devices and other biologics. Results depend heavily on the specific combination and tissue.
Start the lessonPRP · 3 min read
Is PRP covered by insurance? Coverage and regulatory basics
Most PRP is self-pay. This guide outlines insurance coverage, the FDA framework, facility rules and what clinicians need in place before offering PRP.
Start the lessonPRP · 2 min read
What is next for PRP? Exosomes, AI and standardization
PRP research is moving toward standardized preparation, PRP-derived exosomes and AI-based prediction. All of it is still under study.
Start the lessonReady for the hands-on detail?
Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.